AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00079443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01750918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
Study NCT01750918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
Study NCT01750918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil-based chemotherapy
Study NCT03037905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SignatureSuite OR Integration System by STERIS Corporation
Description: SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
Study NCT01666132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intramyocardial injection of BM cells
Description: only intramyocardial, NOGA guided injection on BM cells.
Study NCT01666132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intramyocardial / intracoronary injection of BM cells
Description: combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
Study NCT01666132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best medical therapy
Description: initially no intervention; crossover to therapy 6 months after enrollment
Study NCT02894073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: skin transilluminator
Description: VeinViewer
Study NCT03381040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Lyft
Description: Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
Study NCT03381040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Volyme
Description: Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope.
Study NCT03615105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg IV flat dose
Study NCT03615105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Description: Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.
Study NCT03517085 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX401
Description: DTX401 administered as a single peripheral intravenous (IV) infusion
Study NCT03517085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid regimen
Description: prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
Study NCT03429959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOCKNLEG
Description: Donning and doffing success compared with the two study stockings, wearing the assigned study stocking for a day, Patient Quesationnaire on donning and doffing success and wearing comfort of each study stocking
Study NCT03429959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIGVARIS Cotton
Description: SIGVARIS Cotton
Study NCT01242774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
Study NCT03950336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Prebiotics
Description: Oligofructose-enriched inulin \[a combination of shorter chain oligofructose, Degree of Polymerisation (DP) 3 - 9 and longer chain inulin (DP ≥ 10), in a 50:50 ratio ± 10 %\] 12 g/day for 6 weeks
Study NCT03950336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low n-6 PUFA Diet
Description: The Mediterranean diet pattern (MDP) with increased n-3 PUFA, saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) and reduced n-6 PUFAs food intake will be adopted as suitable Low n-6 PUFA diet.
Study NCT03950336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Maltodextrin consists of D-glucose units connected in chains of variable length (DP 3-17). The glucose units are primarily linked with α(1→4) glycosidic bonds. Maltodextrin is easily hydrolyzed by the intestinal enzymes and thus does not have an effect on colonic microbiota. Maltodextrin (5 g/days for 6 weeks) will be used as a placebo for the prebiotic treatment
Study NCT03950336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Diet
Description: Participants who will not be assigned to Low n-6 PUFA diet will be advised to follow the Canada's Food Guide recommendations (Control diet). As Canada's Food Guide Diet is also designed with the aim to support healthy eating and prevention of metabolic and chronic disorders, this diet may not be considered as a true comparator for the Low n-6 PUFA diet intervention.
Study NCT03460418 — intervention group
Intervention type: OTHER
Intervention: Phone contact
Description: Assessment of the different outcomes by means of a phone contact
Study NCT01160666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
Study NCT04868903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.
Study NCT00033345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pill taken daily during run-in period
Study NCT04545697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medcorder
Description: Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
Study NCT04585360 — intervention group
Intervention type: OTHER
Intervention: Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life
Description: Realization of specific questionnaires evaluating:~* psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~* fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~* quality of life (SF36 self-assessment questionnaire)
Study NCT01794416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic epicardial ablation
Study NCT01794416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial catheter ablation
Study NCT01794416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Study NCT00694161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fx-1006A
Description: Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
Study NCT01731015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Grade Oxygen
Description: At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience \~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
Study NCT01591590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG PET-CT
Description: All patients will undergo FDG PET-CT at inclusion and 2 weeks after
Study NCT01591590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion MRI
Description: All patients will undergo Diffusion MRI at inclusion and 2 weeks later
Study NCT01591590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples (plasma preparation and CTC)
Study NCT03767569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo-inositol and Folic acid daily
Study NCT03767569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Folic Acid
Description: Folic Acid daily
Study NCT03508011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study NCT01684774 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine
Study NCT03274089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kiosk intervention group
Description: SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~* Collects patient information using patient-specific identification~* Prompts the user for answers to screening questions for acute conditions~* Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~* Triages patients based on responses to screening questions, physiological parameters and blood test results~* Provides recommendations to the patient on the care plan, self management and lifestyle choices
Study NCT02668419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulator
Description: Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min.
Study NCT02668419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Session
Description: each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure >15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as >200 mmHg; 6) a rise in diastolic blood pressure during exercise >110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
Study NCT04078399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine combined with interferon preemptive treatment
Description: Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
Study NCT04477122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and extracorporeal radial shock waves therapy
Description: 25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
Study NCT04477122 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual therapy and extracorporeal radial shock waves therapy
Description: 25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
Study NCT02940964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Count on me Singapore (COMS) CPR
Description: Using the song as a mental metronome to guide CPR.
Study NCT02940964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPR
Description: Standard CPR with one-and-two-and-three.... counting
Study NCT03542552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
Study NCT03542552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
Study NCT02621333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Description: platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
Study NCT02621333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
Study NCT02621333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
Study NCT00278824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matrix Transdermal Fentanyl/CHADD Drug Delivery System
Description: Patch applied every 3 days for 15 days
Study NCT00278824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch applied every 3 days for 15 days
Study NCT03968510 — intervention group
Intervention type: PROCEDURE
Intervention: parathyroidectomy
Description: routine parathyroidectomy will be done for the treatment of adenoma
Study NCT02197962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Radial shockwaves
Description: Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
Study NCT02197962 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Radial Shockwaves
Description: Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
Study NCT03490344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: * Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~* Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)
Study NCT03490344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
Study NCT02875288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivicaine
Description: 1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration
Study NCT02875288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivicaine
Description: 1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration
Study NCT03429075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin + Placebo
Description: Multiple dosing days psilocybin vs 6 weeks of daily placebo
Study NCT03429075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin + Escitalopram
Description: Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
Study NCT02845869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THOR Laser LX2 System
Description: Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
Study NCT04408794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant (BHV-3500)
Description: 10 mg IN up to 8 times per month, up to 1 year
Study NCT01424761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 300 mg/d (150 mg/bid)
Study NCT01424761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo :starch
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil 0 mg
Description: Modafinil (0 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Description: Modafinil (200 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Description: Modafinil (400 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 0 mg
Description: Cocaine (0 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 0 mg
Description: Cocaine (0 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 12 mg
Description: Cocaine (12 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 12 mg
Description: Cocaine (12 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 25 mg
Description: Cocaine (25 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 25 mg
Description: Cocaine (25 mg/day)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 50 mg
Description: Cocaine (50 mg/day)
Study NCT03821779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo social exposure
Description: Subjects will be invited to give a 5 minutes oral presentation on the topic of their choice to five examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is prompt to elicit anticipation-type of social anxiety.